An Update on the Role of Digoxin in Older Adults with Chronic Heart Failure

Ali Ahmed, MD, MPH, FACC, FAHA, FESC, associate professor, Division of Gerontology, Geriatric Medicine, and Palliative Care, Department of Medicine, School of Medicine and Department of Epidemiology, School of Public Health, University of Alabama at Birmingham; director, Geriatric Heart Failure Clinics, Veterans Affairs Medical Center, Birmingham, AB, USA.

Heart failure (HF) is the leading cause of hospitalization among older adults. Digoxin has been shown to reduce hospitalization due to worsening HF. However, at the commonly prescribed dose of 0.25 mg/day, digoxin does not reduce mortality. New data suggest that at low doses (0.125 mg/day or lower) digoxin not only reduces hospitalization due to HF, but may also reduce mortality. Further, at lower doses, it also reduces the risk of digoxin toxicity and obviates the need for routine serum digoxin level testing. Digoxin in low doses should be prescribed to older adults with symptomatic HF.
Key words: chronic heart failure, older adults, treatment, digoxin, update.

Warfarin-Drug Interactions among Older Adults

Andrew Liu, BSc Hon, BScPhm, RPh, Clinical Pharmacist, Thrombosis Service, Toronto East General Hospital, Toronto, ON.
Carmine Stumpo, BScPhm, PharmD, RPh, Director, Pharmacy and Emergency Services, Toronto East General Hospital, Toronto, ON.

Warfarin-drug interactions are often encountered in the care of older adults. Interactions may be classified as pharmacokinetic, resulting in changes in serum warfarin concentrations, or pharmacodynamic, resulting in changes in hemostasis or platelet function. Knowledge of these mechanisms of warfarin-drug interactions may help identify warfarin interactions, facilitate prescribing decisions, and assist with appropriate monitoring.
Key words: warfarin, drug interactions, anticoagulants, cytochrome P-450 enzyme system, older adults.

Pharmacological Treatments for Diabetes among Older Adults: An Update

Jeremy Gilbert, MD, FRCPC, Staff Endocrinologist, Toronto General Hospital, Toronto, ON.

Diabetes is a very common condition, especially among older adults. There are numerous benefits associated with improved glycemic control. However, achieving glycemic targets can be challenging, particularly for older adults with comorbidities. In recent years more oral antihyperglycemic agents have become available to better manage diabetes, and there are many pharmacological therapies currently in development. In order to select the most appropriate agent to use as monotherapy or in combination for an individual patient, it is important to be familiar with the mechanism, efficacy, safety, and cost of the various antihyperglycemic agents.
Key words: diabetes, older adults, oral antihyperglycemic agents, monotherapy, combination therapy.

Ischemic Stroke Prevention: Are Two Antiplatelet Agents Better than One in Older Adults?

Sheri L. Koshman, BScPharm, ACPR, PharmD, Assistant Professor of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB.
Glen J. Pearson, BSc, BScPhm, PharmD, FCSHP, Associate Professor of Medicine; Division of Cardiology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB.

Antiplatelet agents are the cornerstone of secondary prevention for patients who present with an ischemic stroke or transient ischemic attack (TIA). At present, monotherapy with acetylsalicylic acid (ASA) or clopidogrel or the combination regimen of ASA plus extended-release dipyridamole are recommended as first-line options in the stroke prevention guidelines. The combination of ASA and clopidogrel is not routinely recommended for secondary stroke prevention, since it has been shown to offer no therapeutic advantage and an increased risk of bleeding. The clear answer as to whether one or two antiplatelet agents are better for the secondary prevention of ischemic stroke events in older adults depends upon the combination of agents, as well as the monotherapy comparator.
Key words: stroke prevention, clopidogrel, acetylsalicylic acid, dipyridamole, antiplatelet agents.

Incontinence among Older Adults

David R. Staskin, MD, Department of Urology, New York Presbyterian Hospital, Weill-Cornell Medical College, New York, NY, USA.
Edward Zoltan, MD, Division of Urology, Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Alan J. Wein, MD, Division of Urology, Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.

Older adults have a high prevalence of urinary incontinence. Among the older adult population, many nonurinary pathological, anatomical, physiological, and pharmacological factors may serve as comorbidities in the development of incontinence. The treating physician must appreciate potentially reversible pathologies. Older adults frequently are prescribed several drugs; therefore, it is important to consider drug-drug metabolic interactions. Age-associated changes may affect pharmacological actions of the drug. Antimuscarinic therapy has been proven efficacious and represents the first line of pharmacologic therapy for overactive bladder (OAB). The selection of an antimuscarinic agent for the management of an older individual presenting with OAB is limited by the natural condition of the aging body and by the side effects associated with antimuscarinics as a class and the specific agents themselves.
Key words: urinary incontinence, antimuscarinics, older adult, frail older adult, geriatrics.

Alcohol and Prescription Drug Interactions Among Aging Adults

Kristine E. Pringle, Ph.D., Health Care Consultant, First Health Services Corporation/PAPACE, Harrisburg, PA, USA.
Frank M. Ahern, Ph.D., Senior Research Associate, Department of Biobehavioral Health, Pennsylvania State University, University Park, PA, USA.
Debra A. Heller, Ph.D., Senior Health Care Consultant, First Health Services Corporation/PA-PACE, Harrisburg, PA, USA.

Many medications have the potential to interact with alcohol, and older patients may be at greater risk of experiencing adverse effects due to issues of comorbidity and polypharmacy. Even small amounts of alcohol consumed by an older person who is taking multiple medications can have serious consequences. A retrospective analysis linked prescription claim records with self-reported alcohol use. Results showed that 77% of older adults used at least one alcohol-interactive medication, and 19% of alcohol-interactive drug users reported concomitant alcohol use. Because many individuals are unaware of the risks posed by alcohol and medications, it is important for clinicians to warn patients about potential interactions.
Keywords: older adults, alcohol, prescription drug use, alcohol-drug interactions, concomitant use of alcohol and prescription drugs.

Psychiatric Side Effects of Nonpsychiatric Medications

The accredited CME learning activity based on this article is offered under the auspices of the CE department of the University of Toronto. Participating physicians are entitled to one (1) MAINPRO-M1 credit by completing this program, found online at www.geriatricsandaging.ca/cme

Kannayiram Alagiakrishnan, FRCP(C), Associate Professor, Division of Geriatric Medicine, Department of Medicine, University of Alberta, Edmonton, AB.
Cheryl A. Wiens, PharmD, Associate Professor, Faculty of Pharmacy & Pharmaceutical Sciences, University of Alberta, Edmonton, AB.

Numerous medications are capable of causing psychiatric side effects. Drug abuse or misuse, polypharmacy, or physiological changes due to aging may lead to these adverse effects. Drug-induced effects on mental health is a topic of considerable clinical importance and yet it is poorly recognized by health care professionals. This article is a review of psychiatric side effects of prescription and over-the-counter medications, problem recognition, and what can be done to manage and prevent these adverse events. Prevention of drug-induced psychiatric side effects can be aided by avoiding, where possible, medications that can cause these effects; evaluating renal and hepatic function on a regular basis; avoiding agents that can cross the blood-brain barrier; and conducting brief cognitive and behavioural assessments at baseline with follow up on a periodical basis.
Key words: psychiatric side effect, renal insufficiency, nonpsychiatric medications, adverse drug reactions, cognitive impairment.

Medication Review for Older Adults

Richard Holland, BA, BM BCh, DA, DPH, MFPH, PhD, Senior Lecturer in Public Health Medicine, School of Medicine Health Policy & Practice, University of East Anglia, Norwich, UK.
David Wright, BPharm, PhD, Senior Lecturer in Pharmacy Practice, School of Chemistry and Pharmacy, University of East Anglia, Norwich, UK.

Older people consume a disproportionate quantity of drugs compared to younger people. Furthermore, the volume and cost of these drugs is increasing markedly. In theory, drugs are prescribed to reduce both morbidity and mortality but can also cause harm, particularly amongst older people. Medication review has been advocated as a technique to reduce such problems, whilst at the same time ensuring patients gain maximum benefit from their drugs. Whilst medication review seems a logical solution to inappropriate prescribing in general and adverse reactions in particular, evidence that specific interventions are effective at reducing morbidity or mortality is lacking.
Key words: medication review, adverse drug reactions, medication appropriateness, pharmacists, background.

Hormone Replacement Therapy in the Older Adult

Karin H. Humphries, MBA, DSC, Division of Cardiology, Department of Medicine, University of British Columbia, Vancouver, BC.
Janet McElhaney, MD, Department of Geriatrics, University of British Columbia, Vancouver, BC.

The growth in information about hormone replacement therapy (HRT) over the past few years has been impressive. This review summarizes the latest information on HRT and cardiovascular disease, osteoporotic fractures, and cognitive function. The risks of HRT (e.g., stroke, breast cancer, and venous thromboembolism) clearly outweigh the benefits (e.g., reduction in osteoporotic fractures). The use of HRT for primary or secondary prevention of coronary heart disease or to decrease the risk of cognitive dysfunction is also not supported. While the evidence in older adults is substantial, there is some controversy regarding the effectiveness of HRT initiated in women at the start of menopause.
Key words: hormone replacement therapy, cardiovascular disease, osteoporosis, cognitive function, dementia.

Aging and the Neurobiology of Addiction

Paul J. Christo, MD, Assistant Professor; Director, Pain Treatment Center & Multidisciplinary Pain Fellowship, Division of Pain Medicine, Department of Anesthesiology and Critical Care, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Greg Hobelmann, MD, Postdoctoral Fellow, Division of Pain Medicine, Department of Anesthesiology and Critical Care, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Amit Sharma, MD, Postdoctoral Fellow, Division of Pain Medicine, Department of Anesthesiology and Critical Care, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. *Current Address: Assistant Professor, College of Physicians & Surgeons of Columbia University, New York, NY.